Levodopa/carbidopa (ND0612) vs Rytary (IPX066)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
Levodopa/carbidopa (ND0612) · Onerji
Marketed by NeuroDerm Ltd.
NCT02577523 · Phase 2 · completed
Participants were randomized to two ND0612 regimens, but the study was only single-blinded for outcome assessors, had no placebo or active-control arm, and was small with 19 participants per group. The clinical primary endpoint was daily OFF time; although the 24-hour regimen showed a numerically greater reduction, statistical significance for the comparison was not reported, so the result is unclear.
Reported efficacy
Change in Daily "OFF" Time (Baseline to Day 28): Change in Daily "OFF" Time (Baseline to Day 28): ND0612 Regimen 1 - 24-hr Infusion -2.8 Hours (95% CI -4.6--0.9) vs ND0612 Regimen 2 - 14-hr Infusion -1.3 Hours (95% CI -3.1-0.5) (unclear)
Result source: NCT02577523
Rytary (IPX066)
Marketed by Amneal Pharmaceuticals
NCT00974974 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled phase 3 trial with 393 randomized participants. The primary clinical endpoint—percentage of waking hours spent in the Parkinsonian “off” state—favored IPX066 over immediate-release carbidopa-levodopa and was statistically significant (p<0.0001).
Reported efficacy
Percentage of "Off" Time During Waking Hours at End of Study (22 weeks): Percentage of "Off" Time During Waking Hours at End of Study (22 weeks): IPX066 23.82 percentage (Standard Deviation 14.91) vs IR CD-LD (Active Comparator) 29.79 percentage (Standard Deviation 15.81) (met)
Result source: NCT00974974
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Levodopa/carbidopa (ND0612) | Rytary (IPX066) |
|---|---|---|
| OFF time, change | -2.1 vs -1.4−0.7 vs placeboNCT01883505 | —Not reported |
| ON time without troublesome dyskinesia, change | —Trial running · NCT04006210 | —Not reported |
| UPDRS Part III, change | —Trial running · NCT04006210 | 21.6 vs 25.5vs IR CD-LDNCT00869791 |
| MDS-UPDRS Part II, change | —Trial running · NCT04006210 | —Not reported |
OFF time, change
- Levodopa/carbidopa (ND0612)
- -2.1 vs -1.4−0.7 vs placeboNCT01883505
- Rytary (IPX066)
- —Not reported
ON time without troublesome dyskinesia, change
- Levodopa/carbidopa (ND0612)
- —Trial running · NCT04006210
- Rytary (IPX066)
- —Not reported
UPDRS Part III, change
- Levodopa/carbidopa (ND0612)
- —Trial running · NCT04006210
- Rytary (IPX066)
- 21.6 vs 25.5vs IR CD-LDNCT00869791
MDS-UPDRS Part II, change
- Levodopa/carbidopa (ND0612)
- —Trial running · NCT04006210
- Rytary (IPX066)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Levodopa/carbidopa (ND0612): 4 of 5 rows · Rytary (IPX066): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Levodopa/carbidopa (ND0612) | Rytary (IPX066) |
|---|---|---|
| PDQ-39 absolute change · score | -6.6 vs -1.8 placebo score @ 2wka,b,c,d NCT01883505 · Phase 2 · registry result, not featured evidence | -6 vs 0.6 placebo score @ 30wk390 mg LDe,a,b,c,d NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 show 2 more doses-3.8 vs 0.6 placebo score @ 30wk245 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 -4.4 vs 0.6 placebo score @ 30wk145 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 |
| Dropout rate | —24-hr Infusionf NCT02577523 · Phase 2 show 4 more results—14-hr Infusion NCT02577523 · Phase 2 0%Period 1. ND0612 NCT01883505 · Phase 2 · registry result, not featured evidence —Period 2. ND0612 NCT01883505 · Phase 2 · registry result, not featured evidence —Period 2. ND0612 + Entacapone NCT01883505 · Phase 2 · registry result, not featured evidence · combination | —g NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3 show 9 more results24.5%390 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 20.2%245 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 17.2%145 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 —Part 1: Conversion NCT01411137 · Phase 3 · registry result, not featured evidence —Part 2: Open-Label Extension 1 NCT01411137 · Phase 3 · registry result, not featured evidence —Part 3: Open-Label Extension 2 NCT01411137 · Phase 3 · registry result, not featured evidence — NCT01130493 · Phase 3 · registry result, not featured evidence 8.1% NCT01096186 · Phase 3 · registry result, not featured evidence — NCT00869791 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —24-hr Infusionf NCT02577523 · Phase 2 show 4 more results—14-hr Infusion NCT02577523 · Phase 2 —Period 1. ND0612 NCT01883505 · Phase 2 · registry result, not featured evidence —Period 2. ND0612 NCT01883505 · Phase 2 · registry result, not featured evidence —Period 2. ND0612 + Entacapone NCT01883505 · Phase 2 · registry result, not featured evidence · combination | —g NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3 show 9 more results15.3%390 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 14.4%245 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 5.7%145 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 —Part 1: Conversion NCT01411137 · Phase 3 · registry result, not featured evidence —Part 2: Open-Label Extension 1 NCT01411137 · Phase 3 · registry result, not featured evidence —Part 3: Open-Label Extension 2 NCT01411137 · Phase 3 · registry result, not featured evidence — NCT01130493 · Phase 3 · registry result, not featured evidence 2.6% NCT01096186 · Phase 3 · registry result, not featured evidence — NCT00869791 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 10.5%24-hr Infusionf NCT02577523 · Phase 2 show 4 more results10.5%14-hr Infusion NCT02577523 · Phase 2 5.3%Period 1. ND0612 NCT01883505 · Phase 2 · registry result, not featured evidence 0%Period 2. ND0612 NCT01883505 · Phase 2 · registry result, not featured evidence 0%Period 2. ND0612 + Entacapone NCT01883505 · Phase 2 · registry result, not featured evidence · combination | 5.5%g NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3 show 9 more results2%390 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 4.8%245 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 4.6%145 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 2.3%Part 1: Conversion NCT01411137 · Phase 3 · registry result, not featured evidence 15.6%Part 2: Open-Label Extension 1 NCT01411137 · Phase 3 · registry result, not featured evidence 25%Part 3: Open-Label Extension 2 NCT01411137 · Phase 3 · registry result, not featured evidence 1.1% NCT01130493 · Phase 3 · registry result, not featured evidence 7% NCT01096186 · Phase 3 · registry result, not featured evidence 0% NCT00869791 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 24-hr Infusionf infusion site nodule 57.9% infusion site erythema 26.3% infusion site bruising 21.1% NCT02577523 · Phase 2 show 4 more results14-hr Infusion infusion site nodule 36.8% infusion site bruising 15.8% infusion site haemorrhage 15.8% NCT02577523 · Phase 2 fatigue 10.5% (placebo 0%) headache 10.5% (placebo 9.1%) abdominal pain lower 5.3% (placebo 0%) NCT01883505 · Phase 2 · registry result, not featured evidence blood creatinine abnormal 12.5% (placebo 0%) dental caries 12.5% (placebo 0%) diarrhoea 12.5% (placebo 0%) NCT01883505 · Phase 2 · registry result, not featured evidence back pain 12.5% (placebo 0%) pain in extremity 12.5% (placebo 9.1%) abdominal pain lower 0% (placebo 0%) NCT01883505 · Phase 2 · registry result, not featured evidence · combination | show 9 more results390 mg LD nausea 20.4% (placebo 8.7%) headache 17.3% (placebo 10.9%) dizziness 12.2% (placebo 5.4%) NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 245 mg LD dizziness 19.2% (placebo 5.4%) nausea 19.2% (placebo 8.7%) headache 12.5% (placebo 10.9%) NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 145 mg LD nausea 13.8% (placebo 8.7%) dizziness 9.2% (placebo 5.4%) headache 6.9% (placebo 10.9%) NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 upper respiratory infection 15.6% anxiety 6.3% fall 6.3% NCT01411137 · Phase 3 · registry result, not featured evidence fall 16.7% orthostatic hypotension 16.7% anxiety 8.3% NCT01411137 · Phase 3 · registry result, not featured evidence dyskinesia 4.5% confusional state 3.4% insomnia 3.4% NCT01130493 · Phase 3 · registry result, not featured evidence anxiety 3.7% fatigue 3.7% feeling of warth in abdomen 3.7% NCT00869791 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 3 versus Phase 2.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 30 weeks versus 2 weeks.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fPopulation comparability has not been reviewed for these studies.
- gPopulation comparability has not been reviewed for 6 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Levodopa/carbidopa (ND0612)
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
Rytary (IPX066)
show 2 more results
show 1 more result
show 2 more results
show 2 more results
show 2 more results
show 3 more results
+ 3 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Levodopa/carbidopa (ND0612)'s landscape · Rytary (IPX066)'s landscape